ESR1 and neoplasm: Compared with patients with mIDC, patients with mILC with de novo metastasis, higher ER positivity, and/or lower tumor grade had better PFS and OS estimates across 15 years, suggesting that long-term prognosis and survival patterns differ between patients with mILC vs those with mIDC.